

A vertical decorative bar on the left side of the slide, featuring a repeating pattern of icons in red and white on a black background. The icons include a pair of binoculars, a heart with a pulse line, a person with their arms raised, and a warning sign (exclamation mark in a circle).

# Melanoma Care in Victoria

Towards optimal care





# Melanoma Summit 2022 Working Party

## **Chairs**

A/Prof Phillip Parente  
A/Prof Victoria Mar

Dr Kortnye Smith  
A/Prof Craig Underhill  
Dr Shelley Walder

## **Members**

Dr Margaret Chua  
Dr Ian Devlin  
Dr Tom Dewar  
A/Prof David Gyorki  
A/Prof Andrew Haydon  
Dr Mahesh Iddawela  
A/Prof David Kok  
Prof Grant McArthur  
A/Prof Paul Mitchell  
Dr George Pratt  
Prof Mark Shackleton

## **Data Analysis**

Ella Stuart  
Norah Finn

## **Tumour Summits Team**

Janine Scott  
Diana Fayle  
Sam Witcher  
Rebecca Miller  
Allira Mitchell  
Lori Cameron



## In this presentation

- An overview of care according to the optimal care pathway stages
- Overview of data sources
- Characteristics of Victorian melanoma population
- Incidence, mortality and survival
- Treatment algorithms for stage I-III melanoma
- Care patterns and variation across Victoria by Integrated Cancer Service
- Volume

Optimal care pathway for people  
with melanoma

SECOND EDITION





## Melanoma Optimal Care Pathway (OCP)

**Prevention  
and early  
detection**

**Presentation,  
initial  
investigations  
and referral**

**Diagnosis,  
staging  
and  
treatment  
planning**

**Treatment**


**Care after  
initial  
treatment  
and  
recovery**

**Managing  
recurrent ,  
residual and  
metastatic  
disease**

**End-of-life  
care**



## Department of Health Linked Data



Data linkage performed by the Centre for Victorian Data Linkage

## Unlinked Data Sources

Cancer Services Performance  
Indicator (CSPI) medical  
record audit 2020

POPulation Level Analysis and Reporting  
(POLAR) - Outcome Health. Participating  
GP data for Eastern Melbourne, South  
East Melbourne and Gippsland Primary  
Health Networks, sourced from MBS  
numbers and SNOMED codes (derived  
by diagnoses) - previously presented



## Features of linked dataset

- State wide data - reliable linkage program
- Population level outcomes - offers general indicative patterns
- Limitations:
  - No data on community care or clinical trials
  - No MBS or PBS data (i.e. no oral anti-cancer therapy data)
  - Relies on hospital coding
  - Hume Regional Integrated Cancer Service (HRICS) – no admitted surgery, sentinel lymph node biopsy or IV anti-cancer therapy data for patients treated in Albury (NSW)




## Registry derived stage at diagnosis in the linked dataset

- Registry-derived stage is available from 2018 onwards
  - Based on tumour, nodes and metastases (TNM) from pathology reports and is staged according to 8<sup>th</sup> ed AJCC
  - Derived based on thickness, ulceration, regional and distant metastases
  - No data on mitosis
  - Clarks level and subsite are also available
- Registry-derived stage is recorded for stage at diagnosis only, or within 120 days from date of diagnosis (diagnostic biopsy/resection)
- Metastatic disease determined from pathology and hospital notifications
- The presentation will be focused on *invasive skin melanoma* (ICD10-AM C43)



# Integrated Cancer Services (ICS) and Cancer Centres





# Demographics



## Demographics of melanoma patients in linked dataset

Variable	Level	Diagnosed 2018-19 N = 5,910
Age	Median [IQR]	67 [55 - 76]
Aboriginal and/or Torres Strait Islander, N (%)	Yes	25 (<1%)
Comorbidity count, N (%) (VAED derived 1 year prior-1 month after dx; Quan 2011; excl. cancer)	0 1 2+	4860 (82%) 690 (12%) 360 (6%)
Sex, N (%)	Male	3390 (57%)
Socioeconomic quintile, N (%)	Most disadvantaged (Q1) Middle (Q2-Q4) Least disadvantaged (Q5)	963 (16%) 3476 (59%) 1433 (24%)

Source: Linked dataset – VCR, VAED 2018-19; IQR – interquartile range.



## Tumour characteristics of melanoma patients in the linked dataset

Variable	Level	Diagnosed 2018-19 N = 5,910
Registry-derived Stage, N (%)	1	4,369 (74%)
	2	887 (15%)
	3	290 (5%)
	4	181 (3%)
	Unknown	183 (3%)
Melanoma thickness, N (%)	< 0.8mm	3,156 (53%)
	≥ 0.8mm and < 1mm	445 (8%)
	≥ 1mm and < 2mm	990 (17%)
	≥ 2mm and < 4mm	588 (10%)
	≥ 4mm	420 (7%)
	Unknown	311 (5%)



## Melanoma site for patients in the linked dataset

ICD10-AM Diagnosis code	Diagnosed 2018-19, N = 5,910 N (column %)		
	Female	Male	Total
C435: Trunk	590 (23%)	1364 (40%)	1956 (33%)
C436: Upper limb, including shoulder	797 (32%)	710 (21%)	1507 (25%)
C437: Lower limb, including hip	709 (28%)	440 (13%)	1149 (19%)
C434: Scalp and neck	125 (5%)	358 (11%)	483 (8%)
C433: Other and unspecified parts of face	189 (8%)	273 (8%)	462 (8%)
C439: Skin, unspecified	60 (2%)	113 (3%)	173 (3%)
C432: Ear and external auricular canal	36 (1%)	114 (3%)	150 (3%)
C431: Eyelid, including canthus	8 (0%)	7 (0%)	15 (0%)
C430: Lip	3 (0%)	8 (0%)	11 (0%)
C438: Overlapping skin	1 (0%)	3 (0%)	4 (0%)

Source: Linked dataset – VCR 2018-19



## Ulceration for Melanoma in the linked dataset, 2018-19 (N = 5,562)

Variable	Level	Ulceration, N (row %)			P-value
		Absent	Present	Unknown	
Melanoma thickness	< 1mm	3321 (92%)	75 (2%)	204 (6%)	<0.001
	≥ 1mm	1290 (66%)	603 (31%)	69 (4%)	
Stage at diagnosis	1	4045 (93%)	83 (2%)	241 (6%)	<0.001
	2	408 (46%)	461 (52%)	18 (2%)	
	3	147 (54%)	116 (43%)	8 (3%)	
	4	11 (31%)	18 (51%)	6 (17%)	
ICS of residence	NEMICS	987 (84%)	138 (12%)	50 (4%)	0.154
	SMICS	1340 (84%)	179 (11%)	84 (5%)	
	WCMICS	605 (83%)	101 (14%)	24 (3%)	
	BSWRICS	443 (83%)	62 (12%)	29 (5%)	
	GRICS	314 (80%)	58 (15%)	22 (6%)	
	HRICS	368 (85%)	42 (10%)	25 (6%)	
	LMICS	307 (81%)	51 (13%)	22 (6%)	
	GICS	247 (79%)	47 (15%)	17 (5%)	
Total	-	4611 (83%)	678 (12%)	273 (5%)	

Source: Linked dataset – VCR 2018-19. Unknown melanoma thickness and unknown stage excluded (N = 348)



## OCP Step 1: Prevention and early detection

**Prevention  
and early  
detection**

**Presentation,  
initial  
investigations  
and referral**

**Diagnosis,  
staging  
and  
treatment  
planning**

**Treatment**

**Care after  
initial  
treatment  
and  
recovery**

**Managing  
recurrent ,  
residual and  
metastatic  
disease**



**End-of-life  
care**



# Incidence, mortality and survival




## Trends in melanoma incidence & mortality in Victoria



Year	Incidence ASR per 100,000		Mortality ASR per 100,000	
	Female	Male	Female	Male
1985	19.2	17.2	2.8	3.2
1990	18.7	22.5	2.3	4.0
1995	25.3	27.8	2.7	4.5
2000	24.5	28.1	2.2	3.7
2005	29.4	34.1	1.9	3.9
2010	22.8	31.5	1.7	4.5
2015	23.8	31.7	1.8	3.8
2020	19.5	26.2	1.0	2.4





# Disparities in melanoma incidence, 2018-20



	More likely to be diagnosed with melanoma
	Not different
	Less likely to be diagnosed with melanoma



## Disparities in melanoma 5-year relative survival, 2015-19





## OCP Step 2: Presentation, initial investigations and referral

Prevention  
and early  
detection

**Presentation,  
initial  
investigations  
and referral**

Diagnosis,  
staging  
and  
treatment  
planning

Treatment

Care after  
initial  
treatment  
and  
recovery

Managing  
recurrent ,  
residual and  
metastatic  
disease

End-of-life  
care



## GP screening and referral data

- Presented by Outcome Health – POLAR data
- Less skin checks/biopsies conducted during 2020
- Less skin checks performed in Gippsland compared to EMPHN and SEMPHN



## OCP Step 3: Diagnosis, staging and treatment planning

Prevention  
and early  
detection

Presentation,  
initial  
investigations  
and referral

**Diagnosis,  
staging  
and  
treatment  
planning**

Treatment

Care after  
initial  
treatment  
and  
recovery


Managing  
recurrent ,  
residual and  
metastatic  
disease

End-of-life  
care




# Stage at diagnosis by ICS of residence, 2018-19 (N = 5,727)

Crude proportions of stage at diagnosis




Stage at diagnosis



Difference between ICS: P-value 0.034

Logistic regression model – Metastatic disease (stage IV) Adjusted for age and sex



Victorian average = 1.0

Significantly lower odds of metastatic disease - SMICS

Significantly higher odds of metastatic disease - GICS



## Melanoma thickness by regionality, 2018-19 (N = 5,910)

Melanoma thickness	Remoteness (ABS)			Total	P-value
	Major cities	Inner regional	Outer regional & remote		
< 1mm	2389 (62%)	992 (61%)	208 (56%)	3601 (61%)	0.238
≥ 1mm	1286 (33%)	556 (34%)	142 (38%)	1998 (34%)	
Unknown	199 (5%)	87 (5%)	24 (6%)	311 (5%)	


Melanoma thickness	ICS of residence								P-value
	NEMICS	SMICS	WCMICS	BSWRICS	GRICS	HRICS	LMICS	GICS	
< 1mm	760 (61%)	1073 (63%)	482 (62%)	337 (59%)	252 (60%)	279 (61%)	230 (57%)	188 (57%)	0.577
≥ 1mm	424 (34%)	543 (32%)	251 (32%)	204 (35%)	144 (34%)	156 (34%)	152 (37%)	124 (37%)	
Unknown	67 (5%)	78 (5%)	42 (5%)	34 (6%)	23 (5%)	24 (5%)	24 (6%)	19 (6%)	

Source: VCR, VAED 2018-20; ABS – Australian Bureau of Statistics; ICS – Integrated Cancer Service; HRICS data limitation




# Socio-economic status in Victoria

Victorian population disadvantage by Local Government Area (for reference)



Relative disadvantage of melanoma patients by ICS of residence, 2018-19 (N = 5872)



Source: VCR, VAED 2018-20; Patients with unknown socio-economic quintile excluded (n=38); HRICS data limitation

Difference between ICS: P-value < 0.001



## Melanoma thickness and stage at diagnosis by socio-economic status, 2018-19 (N = 5,872)

Variable	Level	Socio-economic quintile					P-value
		1 Most disadv	2	3	4	5 Least disadv	
Melanoma thickness	< 1mm	504 (52%)	706 (61%)	711 (60%)	736 (65%)	927 (65%)	<0.001
	≥ 1mm	403 (42%)	390 (34%)	408 (34%)	345 (30%)	432 (30%)	
	Unknown	56 (6%)	56 (5%)	69 (6%)	55 (5%)	74 (5%)	
Stage at diagnosis	1	632 (66%)	848 (74%)	868 (73%)	888 (78%)	1110 (77%)	<0.001
	2	206 (21%)	176 (15%)	179 (15%)	142 (12%)	172 (12%)	
	3	53 (6%)	61 (5%)	57 (5%)	48 (4%)	69 (5%)	
	4	42 (4%)	35 (3%)	42 (4%)	31 (3%)	30 (2%)	
	Unknown	30 (3%)	32 (3%)	42 (4%)	27 (2%)	52 (4%)	


Source: VCR, VAED 2018-20; Patients with unknown socio-economic quintile excluded (n=38)



# Documented multidisciplinary team meetings below 85% target

Documentation of MDM recommendations in the health record ensures such information is accessible to all team members

CSPI 2018 diagnoses, N=310



Target=85%  
State-wide=37%


## Documented MDM (2020)

All tumour streams – 70%  
Lung cancer – 74%  
Breast cancer – 85%  
Colorectal cancer – 76%

Patients are audited at the health service where they received their **first treatment**.

Some regional patients will be audited at a metro ICS health service.

CSPI 2020 diagnoses, N=313



Target=85%  
State-wide=40%

De-identified health service


Source: Cancer Services Performance Indicator (CSPI) audit 2018 and 2020; \*HRICS data limitation – missing data from Albury Wodonga Health – Albury campus;



# Decrease in recording of stage in multidisciplinary team meeting recommendations

This indicator measures whether stage was recorded in the MDM documentation in the patient's health record

CSPI 2018 MDM, N=115




- Target=85%  
- State-wide=83%

**Stage recorded (2020)**  
All tumour streams – 72%  
Lung cancer – 73%  
Breast cancer – 78%  
Colorectal cancer – 80%

Patients are audited at the health service where they received their **first treatment**.

Some regional patients will be audited at a metro ICS health service.

CSPI 2020 MDM, N=126



- Target=85%  
- State-wide=56%

Multiple ICS health services

Source: Cancer Services Performance Indicator (CSPI) health record audit 2018 and 2020; \*HRICS data limitation – missing data from Albury Wodonga Health – Albury campus;



# Documented supportive care screening below 80% target

A validated supportive care screening tool must be used, such as the NCCN Distress Thermometer and problem checklist


## Supportive care screening (2020)

- All tumour streams – 32%
- Lung cancer – 50%
- Breast cancer – 47%
- Colorectal cancer – 25%


Patients are audited at the health service where they received their **first treatment**.

Some regional patients will be audited at a metro ICS health service.

CSPI 2018 diagnoses, N=310



CSPI 2020 diagnoses, N=313



De-identified health service

Source: Cancer Services Performance Indicator (CSPI) health record audit 2018 and 2020; \*HRICS data limitation – missing data from Albury Wodonga Health – Albury campus;



## OCP Step 4: Treatment

Prevention  
and early  
detection

Presentation,  
initial  
investigations  
and referral

Diagnosis,  
staging  
and  
treatment  
planning

**Treatment**

Care after  
initial  
treatment  
and  
recovery

Managing  
recurrent ,  
residual and  
metastatic  
disease

End-of-life  
care



## Admitted surgery within 1 year of diagnosis for melanoma <1mm by ICS of residence, 2018-2019 (N = 3,456)

ICS of residence	Total patients, N	Surgery in hospital, n (row %)	Sentinel lymph node biopsy, n (row %)	No treatment identified in linked data, n (row %)
NEMICS	759	378 (50%)	34 (4%)	374 (49%)
SMICS	1072	498 (46%)	47 (4%)	569 (53%)
WCMICS	482	247 (51%)	26 (5%)	233 (48%)
BSWRICS	337	134 (40%)	19 (6%)	198 (59%)
GRICS	252	101 (40%)	13 (5%)	148 (59%)
HRICS (West)*	136	51 (38%)	5 (4%)	85 (62%)
LMICS	230	113 (49%)	6 (3%)	115 (50%)
GICS	188	109 (58%)	9 (5%)	78 (41%)
<b>Victoria</b>	<b>3456</b>	<b>1631 (47%)</b>	<b>159 (5%)</b>	<b>1800 (52%)</b>


	Above Victorian average - P < 0.05
	Below Victorian average - P < 0.05

Source: VCR 2018-19, VAED 2018-20; Stage I, II and III patients only; \* HRICS data limitation - Patients who live in HRICS Border East excluded due to missing treatment data (n = 143)



# Odds of treatment within 1 year of $\geq 1$ mm melanoma diagnosis, 2018-2019 (N = 1,854)

Adjusted for age, sex, comorbidities




Source: VCR 2018-19, VAED 2018-20, VRMDS 2018-20;

Stage I, II and III patients only; \*HRICS data limitation - Patients who live in HRICS Border East excluded due to missing treatment data (n = 74)




# Time from diagnosis to admitted surgery by melanoma thickness and ICS of treatment, 2018-2019

Melanoma thickness < 1mm  
N = 1,591



Melanoma thickness ≥ 1mm  
N = 1,526




Above Victorian  
average P < 0.05

Below Victorian  
average P < 0.05



# Time from diagnosis to admitted surgery by SLNB and ICS of treatment, 2018-2019 (N = 3,123)




Source: VCR, VAED 2018-20. Restricted to those treated with surgery within 90 days of diagnosis; Restricted to stage I-III melanomas.

\*HRICS data limitation – missing data from Albury Wodonga Health – Albury campus; SLNB – Sentinel lymph node biopsy



# Admitted surgery within 8 weeks of stage I-III melanoma diagnosis by hospital, 2018-2019 (N = 3,123)

Surgery within 8 weeks by hospital



### Hospital outliers

- 1 below average ( $p < 0.05$ )
- 2 below average ( $p < 0.001$ )
- 2 above average ( $p < 0.05$ )
- 63 above average ( $p < 0.001$ )

### Surgical hospital ICS

- NEMICS
- SMICS
- WCMICS
- BSWRICS
- GRICS
- HRICS
- LMICS
- GICS

Surgery within 8 weeks by hospital type

Hospital type	Admitted surgery within: n (% row)	
	4 wks	8 wks
Public, N = 1,488	476 (32%)	1,274 (86%)
Private, N = 1,635	1,236 (76%)	1,581 (97%)
Victoria	1,712 (55%)	2,855 (91%)

	Above Victorian average - $P < 0.05$
	Below Victorian average - $P < 0.05$



## Patient flow for stage I-III melanoma admitted surgery, 2018-2019 (N = 3,081)

ICS of treatment	ICS of residence N (column %)							
	NEMICS	SMICS	WCMICS	BSWRICS	GRICS	HRICS*	LMICS	GICS
NEMICS	377 (54%)	24 (3%)	49 (12%)		19 (9%)	15 (8%)		
SMICS	129 (18%)	741 (81%)	75 (18%)	26 (10%)	57 (28%)	31 (16%)	25 (12%)	13 (6%)
WCMICS	191 (27%)	152 (17%)	292 (70%)	19 (7%)	73 (35%)	64 (33%)	54 (25%)	28 (14%)
BSWRICS				221 (82%)				
GRICS					58 (28%)			
HRICS*						79 (41%)		
LMICS							119 (56%)	
GICS								150 (74%)
Victoria	697	917	416	266	207	189	198	191


**65% of patients had admitted surgery locally**



## Variation in proportion of stage I-III melanoma patients having admitted surgery locally, 2018-2019 (N = 3,123)

**Significantly more** patients having admitted surgery locally:  
BSWRICS, SMICS and GICS

**Significantly less** patients having admitted surgery locally:  
NEMICS, LMICS, HRICS\* and GRICS





## Patient flow for stage I-III melanoma sentinel lymph node biopsy, 2018-2019 (N = 1,144)

ICS of treatment	ICS of residence N (column %)							
	NEMICS	SMICS	WCMICS	BSWRICS	GRICS	HRICS*	LMICS	GICS
NEMICS	86 (35%)		12 (7%)			8 (11%)		
SMICS	44 (18%)	220 (69%)	37 (22%)	15 (12%)	25 (27%)	10 (14%)	10 (13%)	9 (13%)
WCMICS	114 (47%)	90 (28%)	123 (72%)	17 (13%)	50 (53%)	42 (57%)	37 (49%)	21 (31%)
BSWRICS				93 (73%)				
GRICS					14 (15%)			
HRICS*						12 (16%)		
LMICS							21 (28%)	
GICS								34 (50%)
Victoria	244	310	172	125	89	72	68	64

**51% of patients had a sentinel lymph node biopsy locally**



## Patient flow for stage I-III breast cancer sentinel lymph node biopsy, 2018-2019 (N = 6,268)

ICS of treatment	ICS of residence N (column %)							
	NEMICS	SMICS	WCMICS	BSWRICS	GRICS	HRICS*	LMICS	GICS
NEMICS	1081 (68%)	57 (3%)	87 (8%)			54 (17%)		
SMICS	141 (9%)	1482 (83%)	28 (2%)		88 (24%)		10 (3%)	
WCMICS	360 (23%)	242 (14%)	1036 (90%)	16 (3%)	59 (16%)	123 (40%)	95 (27%)	45 (15%)
BSWRICS				443 (96%)				12 (4%)
GRICS					207 (57%)			
HRICS*						126 (41%)		
LMICS							220 (62%)	
GICS							18 (5%)	239 (78%)
Victoria	1582	1781	1151	459	354	303	342	296


**76% of patients had a sentinel lymph node biopsy locally**



## Variation in proportion of stage I-III melanoma patients having a sentinel lymph node biopsy locally, 2018-2019 (N = 1,173)


**Significantly more** patients  
having a SLNB locally:  
BSWRICS, WCMICS and SMICS

**Significantly less** patients  
having a SLNB locally:  
NEMICS, LMICS, HRICS\* and  
GRICS





# Sentinel lymph node biopsy hospital volume in Victoria, 2020 and 2021



Number of hospitals – NEMICS - 17 , SMICS - 18, WCMICS - 16, BSWRICS - 7, GRICS - 7, HRICS\* - 5, LMICS - 6, GICS - 4



## OCP Step 5: Care after initial treatment and recovery

Prevention  
and early  
detection

Presentation,  
initial  
investigations  
and referral

Diagnosis,  
staging  
and  
treatment  
planning

Treatment

Care after  
initial  
treatment  
and  
recovery

Managing  
recurrent ,  
residual and  
metastatic  
disease

End-of-life  
care



# 5 year survival by melanoma stage and ICS of residence

Models adjusted for age, sex and comorbidities

## Stage I


Significantly poorer survival in LMICS

## Stage II

Significantly better survival in HRICS

## Stage III and Stage IV

No significant difference between ICS







# COVID impacts



# Relative difference (95% CI) between observed and expected melanoma diagnoses in 2020 by sex and stage




350 fewer melanoma diagnoses in 2020 than expected



## COVID impacts

### Melanoma surgery trends in cancer patients admitted to hospital

Grey line is forecast based on 2014-2019 data, accounting for seasonality





# Consumer identified areas for improvement



## Consumer identified areas of improvement

- The need for improved knowledge and management of symptoms and side effects
- The need for written, rather than verbal, treatment and discharge plans
- The need for well-coordinated care and information transfer to GPs
- The need for more specialist melanoma nurses



# Summary and variations



## Summary and potential unwarranted variations

### OCP step 1: Prevention and early screening

- Mortality rates have dropped for both male & female over last 5 years
- Incidence was increasing but has reduced in last 5 years
  - Least disadvantaged more likely to be diagnosed with melanoma compared to Victorian average
  - WCMICS & NEMICS residents are less likely to be diagnosed with melanoma and SMICS and regional ICS more likely
- Five-year survival
  - Least disadvantaged have better survival and most disadvantaged have poorer survival
  - SMICS demonstrates significantly better survival rates for men
  - Australian born have poorer survival rates



## Summary and potential unwarranted variations

### OCP step 2: Presentation, initial investigations and referral

- Less skin checks and biopsies completed in primary care during 2020 (EMPHN, SEMPHN, Gippsland PHN)



## Summary and potential unwarranted variations

### OCP step 3: Diagnosis, staging and treatment planning

- SMICS demonstrates significantly lower odds of metastatic disease
- GICS demonstrate significantly higher odds of metastatic disease
- Melanoma thickness
  - higher rate of thickness >1mm for outer regional and remote
  - higher rate of thickness >1mm for most disadvantaged
  - higher stage at diagnosis for most disadvantaged



## Summary and potential unwarranted variations

### OCP step 3: Diagnosis, staging and treatment planning (cont)

- Documented MDM rate below 85% target
  - State average – 40% (slight increase from 37% in 2018 audit)
  - Lower rate than other tumour streams – only 1 campus achieved target (SMICS)
  - Decrease in documentation of stage at MDM (56% in 2020, 83% in 2018)
- Documented supportive care screening is below 80% target
  - Statewide average 12% - significantly lower than other tumour streams
  - Only 1 campus achieved target (BSWRICS)



## Summary and potential unwarranted variations

### OCP step 4: Treatment

#### **Treatment within 1 year of diagnosis <1mm**

Surgery in hospital by ICS of residence

- GICS – above Victorian average
- BSWRICS, GRICS & HRICS West\* – below Vic Average

#### **Treatment within 1 year of diagnosis $\geq$ 1mm**

- SMICS above average for surgery in hospital
- WCMICS above average for SLNB
- LMICS below average for surgery in hospital and IV anti-cancer therapy



## Summary and potential unwarranted variations

### OCP step 4: Treatment (cont)

#### **Time from diagnosis to admitted surgery Stage I-III**

- Surgery within 4 weeks – most ICS are above average - data indicates WCMICS is below average
- Surgery within 8 weeks – most ICS are average or above - data indicates WCMICS is below average
- Surgery within 8-weeks funnel plot shows-
  - 3 campuses below average outliers (WCMICS, SMICS)
  - 65 campuses above average outliers (Multiple ICS)
- Variation in sentinel lymph node biopsy hospital volume –ranged from 1 to over 350 SLNBs per year



## Summary and potential unwarranted variations

### OCP step 4: Treatment (cont)

- Patient flow – admitted surgery
  - NEMICS, LMICS, HRICS\* and GRICS had significantly less patients having surgery locally (WCMICS average)
  - BSWRICS, GICS and SMICS had significantly more patients having surgery locally
- Patient flow - SLNB
  - NEMICS, LMICS, HRICS\* and GRICS had significantly less patients having a SLNB locally (GICS average)
  - BSWRICS, WCMICS and SMICS had significantly more patients having a SLNB locally



## Summary and potential unwarranted variations

### OCP step 5: Care after initial treatment and recovery

#### Survival by stage:

- LMICS has significantly poorer survival for stage I
- HRICS\* had significantly better survival for stage II
- No statistical significant difference in survival for stage III and IV across all ICS



## Summary and potential unwarranted variations

### COVID Impacts

- 350 fewer melanoma diagnoses in 2020 than expected
- 12% reduction in melanoma surgeries in 2020 & 2021



## Prioritised potential unwarranted variations

1. Incidence and survival – regional areas have a higher incidence and lower survival rate for <1mm thickness reaching statistical significance in LMICS
2. MDM documentation rates of 40% are significantly less than 85% target and other tumour streams with variation across ICS
3. Supportive care screening documentation rates of 12% are well below the 80% target with variation across ICS (*consumer identified*)



## Prioritised potential unwarranted variations continued

4. There is variation in treatment delivered (*consumer identified*), timeliness and local access across the state
  - There is significant variation in proportion of stage 1-3 melanoma patients having a sentinel lymph node biopsy locally. LMICS, NEMICS, HRICS\* and GRICS less likely to receive this locally (including when compared to SLNB for breast cancer)
  - There is variation in patient flow across the State with GRICS, LMICS, NEMICS, HRICS\* residents less likely to receive surgery locally



## Prioritised potential unwarranted variations continued

### 5. Consumer identified potential variations

- The need for improved knowledge and management of symptoms and side effects
- The need for written, rather than verbal, treatment and discharge plans
- The need for well-coordinated care information transfer to GPs
- The need for more specialist Melanoma nurses



## Acknowledgements and thank you to...

### Data

**Kathryn Whitfield/Karen Botting** – Department of Health (DH) Linked Dataset,  
CSPI Audit

Victorian Cancer Registry (CCV)

The Centre for Victorian Data Linkage

### Data Analysts

**Ella Stuart** and **Norah Finn** (CCV / DH)

### Funders of Victorian Tumour Summits

Tumour Summits is funded by the Victorian Government and are an initiative of the Victorian Integrated Cancer Services (VICS)

### Tumour Summits team

**Janine Scott**  
**Sam Witcher**

**Diana Fayle**  
**Rebecca Miller**

**Allira Mitchell**  
**Lori Cameron**